Multiple Myeloma
Conditions
Brief summary
This is a Phase I, open-label, multicenter study to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary efficacy of SHR-3836 in patients with multiple myeloma (MM).
Interventions
DRUGSHR-3836 administered as multiple doses.
* In the dose escalation phase, doses are escalated sequentially from low to high levels. * In the dose expansion phase, one or more selected dose levels are further evaluated.
Sponsors
Shanghai Hengrui Pharmaceutical Co., Ltd.
Study design
Allocation
NA
Intervention model
SEQUENTIAL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Age ≥ 18 years, male or female 2. Expected survival ≥ 3 months 3. ECOG performance status 0 or 1 4. Diagnosed with active multiple myeloma per IMWG criteria 5. Relapsed or refractory multiple myeloma and refractory to the most recent line of therapy. 6. Disease progression or non-response to the most recent therapy 7. Measurable disease as defined by serum/urine M-protein or serum free light chain 8. Adequate bone marrow, hepatic, renal, and coagulation function 9. Female participants of childbearing potential and male participants with partners of childbearing potential must agree to use effective contraception 10. Willing and able to provide written informed consent and comply with study procedures
Exclusion criteria
1. Diagnosis of amyloidosis, plasma cell leukemia, Waldenström's macroglobulinemia, or POEMS syndrome. 2. Central nervous system involvement by tumor. 3. History of ≥ Grade 3 CRS with prior T-cell redirecting therapy. 4. Requirement for dialysis or plasmapheresis within 14 days prior to study drug. 5. Prior treatment-related AEs not recovered to ≤ Grade 1 (except alopecia, peripheral neuropathy, or controlled endocrinopathies). 6. Concurrent participation in another clinical study. 7. Prior anti-tumor therapy within specified washout periods. 8. Major surgery within 28 days prior to informed consent or planned during the study. 9. Live attenuated vaccine within 4 weeks prior to first dose or planned during the study. 10. Significant comorbidity that in the investigator's judgment would interfere with study participation or safety. 11. Active autoimmune disease (except controlled type I diabetes, hypothyroidism, or vitiligo). 12. Active infection. 13. Known hypersensitivity or contraindication to SHR-3836.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Determination of Phase II Dose (RP2D) of SHR-3836 | 24 months |
Secondary
| Measure | Time frame |
|---|---|
| Incidence and severity of adverse events (AE) of SHR-3836 | 24 months |
| Maximum plasma concentration (Cmax) | 24 months |
| Time to reach Cmax (Tmax) | 24 months |
| Objective response rate (ORR) | 24 months |
Countries
China
Contacts
CONTACTDepei Wu
Outcome results
None listed